Outcomes and Patterns of Recurrence for Anaplastic Thyroid Cancer Treated With Comprehensive Chemoradiotherapy

Gao, Robert W.; Foote, Robert L.; Garces, Yolanda I.; Daniel, J.; Neben-Wittich, M.A.; Routman, David M.; Patel, Samir H.; Ko, Stephen; McGee, L.A.; Bible, Keith C.; Chintakuntlawar, Ashish V.; Ryder, Mabel; Morris, John C.; Abel, Kathryn M. Van; Rivera, Michael; Abraha, Feven; Lester, Scott C.

doi:10.1016/j.prro.2021.10.006

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This IMRT technique is important to deliver the optimal dose to the different treatment volumes which most often include the operative bed, the thyroid, and lymph node areas I to VI with the upper mediastinum up to the carina [ 63 , 78 , 79 , 89 , 95 ]. Few relapses at the edge of the radiotherapy field (less than 10% marginal relapses) have been reported [ 96 , 97 ]. The rate of loco-regional failure rate may relate to the extent of the EBRT field, as reported by Kim et al, with a five-year local control rate of 40% in ATC patients treated with a large extended field ( n = 12) (such as described before) vs. 9% in case of limited field EBRT ( n = 11) to involved site (tumor and node) ( p = 0.04).…”

Section: Treatment: To Treat Aggressively or To Palliate The Symptoms?mentioning

confidence: 99%

Anaplastic Thyroid Carcinoma: An Update

Jannin

Escande

Ghuzlan

et al. 2022

Cancers

View full text Add to dashboard Cite

Anaplastic thyroid carcinoma (ATC) is a rare and undifferentiated form of thyroid cancer. Its prognosis is poor: the median overall survival (OS) of patients varies from 4 to 10 months after diagnosis. However, a doubling of the OS time may be possible owing to a more systematic use of molecular tests for targeted therapies and integration of fast-track dedicated care pathways for these patients in tertiary centers. The diagnostic confirmation, if needed, requires an urgent biopsy reread by an expert pathologist with additional immunohistochemical and molecular analyses. Therapeutic management, defined in multidisciplinary meetings, respecting the patient’s choice, must start within days following diagnosis. For localized disease diagnosed after primary surgical treatment, adjuvant chemo-radiotherapy is recommended. In the event of locally advanced or metastatic disease, the prognosis is very poor. Treatment should then involve chemotherapy or targeted therapy and decompressive cervical radiotherapy. Here we will review current knowledge on ATC and provide perspectives to improve the management of this deadly disease.

show abstract